Effect of steady state drug-drug interaction on safety and pharmacokinetics with Esuberapost and Ambrisentan in healthy adult subjects

Trial Profile

Effect of steady state drug-drug interaction on safety and pharmacokinetics with Esuberapost and Ambrisentan in healthy adult subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Jul 2017

At a glance

  • Drugs Esuberaprost (Primary) ; Ambrisentan
  • Indications Pulmonary arterial hypertension
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 11 Jul 2017 New trial record
    • 24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top